ProQR Therapeutics, a company dedicated to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, announced that it will launch a series of Expert Perspectives calls to provide an in-depth review of topics related to the company’s pipeline and platform.
The inaugural call in the series will be hosted on June 22 at 12pm EDT and will focus on Usher syndrome and retinitis pigmentosa, The call will feature a fireside chat between Aniz Girach, MD, Chief Medical Officer of ProQR Therapeutics, and Robert Koenekoop, MD, PhD of McGill University/Montreal Children’s Hospital. Drs. Girach and Koenekoop will also discuss QR-421a, ProQR’s investigational therapy for patients with Usher syndrome type 2A and retinitis pigmentosa. They will discuss the role of genetic testing and outcome measures related to visual field and visual acuity, including OCT EZ area, DAC, FST, and BCVA. Additionally, they will discuss relative significance of slowing disease progression, stabilization, and visual improvement. An Usher syndrome patient will be participating in the call to discuss her experience with the disease.
Future topics for the Expert Perspectives call series are planned, including autosomal dominant retinitis pigmentosa and ProQR’s RNA oligonucleotide platform and Axiomer RNA editing approaches.
Date/Time: June 22, 2020, 12-1pm EDT
Topic: Usher syndrome and retinitis pigmentosa